1, 2. Akhe uhlathulule lokho uJesu akwenzela abapostoli bakhe abathembekileko ngemva kokugidinga iPhasika ngo-33 C.E. Study 2 (Phoenix 2) was similar in design except that partial responders (> PASI 50 but < PASI 75) were randomized at week 28 to continue therapy every 12 weeks or increased to every 8 weeks. PASI 75 response rates were 67% in the two 45 mg groups, 66% and 76% in the 90 mg group, and 3% and 4% for placebo. PGA success rates were similar in magnitude. In Study 1, 89% of subjects that were responders at week 28 and week 40 were still responders at week 52 on maintenance therapy compared to 63% who were withdrawn from therapy.1 In Study 2, increased dosing frequency improved treatment success in partial responders for those initiated on 90 mg but not 45 mg.5 UShezi uthe ubudlelwane bakhe noRorke obukhethekile obuphakathi komqeqeshi nomsubathi busukela ebunganini babo besikhathi eside. ‘Uthando luka-Jonathan lwezeSayensi Yezemidlalo luyangigqugquzela ukuze ngifunde kakhulu futhi ngiqhubekele phambili e-UKZN ngoba sengibonile ukuthi ulwazi olutholakala kulo mkhakha lungakwazi ukugqugquzela imiphakathi nabantu ukuze baphumelele futhi basebenze ngokuzimela, kusho uShezi.